244 related articles for article (PubMed ID: 25672369)
1. Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2.
Fenning RS; Burgert ME; Hamamdzic D; Peyster EG; Mohler ER; Kangovi S; Jucker BM; Lenhard SC; Macphee CH; Wilensky RL
J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25672369
[TBL] [Abstract][Full Text] [Related]
2. Lp-PLA2, plaque inflammation and lesion development vary fundamentally between different vascular sites.
Marsche G
J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25672370
[No Abstract] [Full Text] [Related]
3. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.
Wang WY; Zhang J; Wu WY; Li J; Ma YL; Chen WH; Yan H; Wang K; Xu WW; Shen JH; Wang YP
PLoS One; 2011; 6(8):e23425. PubMed ID: 21909350
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.
Wilensky RL; Shi Y; Mohler ER; Hamamdzic D; Burgert ME; Li J; Postle A; Fenning RS; Bollinger JG; Hoffman BE; Pelchovitz DJ; Yang J; Mirabile RC; Webb CL; Zhang L; Zhang P; Gelb MH; Walker MC; Zalewski A; Macphee CH
Nat Med; 2008 Oct; 14(10):1059-66. PubMed ID: 18806801
[TBL] [Abstract][Full Text] [Related]
6. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Riley RF; Corson MA
IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
[TBL] [Abstract][Full Text] [Related]
7. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.
Shi Y; Zhang P; Zhang L; Osman H; Mohler ER; Macphee C; Zalewski A; Postle A; Wilensky RL
Atherosclerosis; 2007 Mar; 191(1):54-62. PubMed ID: 16765356
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.
Hu MM; Zhang J; Wang WY; Wu WY; Ma YL; Chen WH; Wang YP
Acta Pharmacol Sin; 2011 Oct; 32(10):1253-8. PubMed ID: 21970837
[TBL] [Abstract][Full Text] [Related]
9. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.
Lv SL; Zeng ZF; Gan WQ; Wang WQ; Li TG; Hou YF; Yan Z; Zhang RX; Yang M
Acta Pharmacol Sin; 2021 Dec; 42(12):2016-2032. PubMed ID: 34226664
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib.
Acharya NK; Levin EC; Clifford PM; Han M; Tourtellotte R; Chamberlain D; Pollaro M; Coretti NJ; Kosciuk MC; Nagele EP; Demarshall C; Freeman T; Shi Y; Guan C; Macphee CH; Wilensky RL; Nagele RG
J Alzheimers Dis; 2013; 35(1):179-98. PubMed ID: 23388174
[TBL] [Abstract][Full Text] [Related]
11. [Clinical role of lipoprotein-associated phospholipase A2].
Miklishanskaia SV; Liakishev AA; Kukharchuk VV
Kardiologiia; 2013; 53(3):59-70. PubMed ID: 23548429
[TBL] [Abstract][Full Text] [Related]
12. Community-based statins and advanced carotid plaque: Role of CD163 positive macrophages in lipoprotein-associated phospholipase A
Otsuka F; Zhao X; Trout HH; Qiao Y; Wasserman BA; Nakano M; Macphee CH; Brandt M; Krug-Gourley S; Guo L; Ladich ER; Cheng Q; Davis HR; Finn AV; Virmani R; Kolodgie FD
Atherosclerosis; 2017 Dec; 267():78-89. PubMed ID: 29101839
[TBL] [Abstract][Full Text] [Related]
13. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
[TBL] [Abstract][Full Text] [Related]
14. Darapladib for the treatment of cardiovascular disease.
Campos CM; Suwannasom P; Koenig W; Serruys PW; Garcia-Garcia HM
Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):33-48. PubMed ID: 25521799
[TBL] [Abstract][Full Text] [Related]
15. Chronic inhibition of lipoprotein-associated phospholipase A
Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
[TBL] [Abstract][Full Text] [Related]
16. Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature.
Mohler ER; Sarov-Blat L; Shi Y; Hamamdzic D; Zalewski A; Macphee C; Llano R; Pelchovitz D; Mainigi SK; Osman H; Hallman T; Steplewski K; Gertz Z; Lu MM; Wilensky RL
Arterioscler Thromb Vasc Biol; 2008 May; 28(5):850-5. PubMed ID: 18276914
[TBL] [Abstract][Full Text] [Related]
17. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
18. Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model.
Wihastuti TA; Heriansyah T; Hanifa H; Andarini S; Sholichah Z; Sulfia YH; Adam AA; Refialdinata J; Lutfiana NC
Endocr Regul; 2018 Apr; 52(2):69-75. PubMed ID: 29715185
[TBL] [Abstract][Full Text] [Related]
19. Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis.
Guibbal F; Bénard S; Patché J; Meneyrol V; Couprie J; Yong-Sang J; Meilhac O; Jestin E
Bioorg Med Chem Lett; 2018 Feb; 28(4):787-792. PubMed ID: 29336874
[TBL] [Abstract][Full Text] [Related]
20. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
